Free
Education  |   October 1988
Is the Metabolism of Alfentanil Subject to Debrisoquine Polymorphism? A Study Using Human Liver Microsomes
Author Affiliations & Notes
  • Karel L. M. Lavrijsen, Ph.D.
    *
  • Jos M. G. Van Houdt, Grad. Chem.
  • Dirk M. J. Van Dyck, Grad. Chem.
  • Jan J. J. M. Hendrickx, Grad. Chem.
  • Robert J. H. Woestenborghs, Chem. Eng.
    *
  • William Lauwers, Ph.D.
  • Willem E. G. Meuldermans, Ph.D.
    *
  • Joseph J. P. Heykants, Ph.D.
    §
  • * Group Leader, Department of Drug Metabolism and Pharmacokinetics.
  • Staff Member, Department of Drug Metabolism and Pharmacokinetics.
  • Group Leader, Department of Analytical Research.
  • § Director, Department of Drug Metabolism and Pharmacokinetics.
  • McDonnell TE, Bartkowski RR, Kahn C: Evidence for polymorphic oxidation of alfentanil in man (abstract). ANESTHESIOLOGY 61:A284, 1984.
  • ** Kahn C, Rubenfield H, Bartkowski R, McDonnell TE: Competitive inhibition of debrisoquine and phenacetin oxidation by alfentanil in human liver (abstract). North American Symposium on Risk Assessment and the Biological Fate of Xenobiotics, Florida, International Society for the Study of Xenobiotics, 1985, p 31.
Article Information
Education
Education   |   October 1988
Is the Metabolism of Alfentanil Subject to Debrisoquine Polymorphism? A Study Using Human Liver Microsomes
Anesthesiology 10 1988, Vol.69, 535-540. doi:
Anesthesiology 10 1988, Vol.69, 535-540. doi:
First Page Preview
First page PDF preview
First page PDF preview ×
View Large